{"id":"NCT02023879","sponsor":"Sanofi","briefTitle":"Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Alirocumab in Patients With Primary Hypercholesterolemia Not Treated With a Statin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12-16","primaryCompletion":"2014-10-27","completion":"2017-06-30","firstPosted":"2013-12-30","resultsPosted":"2017-03-15","lastUpdate":"2018-07-27"},"enrollment":233,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolemia"],"interventions":[{"type":"DRUG","name":"Alirocumab","otherNames":["SAR236553","REGN727","PraluentÂ®"]},{"type":"DRUG","name":"Placebo (for Alirocumab)","otherNames":[]},{"type":"DRUG","name":"Non-statin LMT","otherNames":[]},{"type":"OTHER","name":"Diet Alone","otherNames":[]}],"arms":[{"label":"Placebo Q2W","type":"PLACEBO_COMPARATOR"},{"label":"Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator)","type":"OTHER"},{"label":"Alirocumab 150 mg Q4W/Up to 150 mg Q2W","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by a regimen of Alirocumab including a starting dose of 150 mg every 4 weeks (Q4W) as add-on to non-statin lipid modifying background therapy or as monotherapy in comparison with placebo in participants with primary hypercholesterolemia not treated with a statin.\n\nSecondary Objective:\n\n* To evaluate the effects on other lipid parameters of Alirocumab 150 mg Q4W versus placebo.\n* To evaluate the safety and tolerability of Alirocumab 150 mg Q4W.\n\nAlirocumab 75 mg Q2W was added as a calibrator arm.","primaryOutcome":{"measure":"Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis)","timeFrame":"From Baseline to Week 24","effectByArm":[{"arm":"Placebo Q2W","deltaMin":4.7,"sd":2.3},{"arm":"Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator)","deltaMin":-53.5,"sd":1.6},{"arm":"Alirocumab 150 mg Q4W/Up to 150 mg Q2W","deltaMin":-51.7,"sd":2.3}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":3},"locations":{"siteCount":43,"countries":["United States","Australia","Belgium","Canada","Denmark","Netherlands","New Zealand","Spain"]},"refs":{"pmids":["27625344"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":58},"commonTop":["Viral upper respiratory tract infection","Arthralgia","Headache","Upper respiratory tract infection","Fall"]}}